Product Images Bimzelx
View Photos of Packaging, Labels & Appearance
- Figure 1 - bimzelx 01
- Figure 2 - bimzelx 02
- Figure A - bimzelx 03
- Figure B - bimzelx 04
- Figure C - bimzelx 05
- Figure D - bimzelx 06
- Figure E - bimzelx 07
- Figure F - bimzelx 08
- Figure G - bimzelx 09
- Figure H - bimzelx 10
- Figure I - bimzelx 11
- Figure A - bimzelx 12
- Figure B - bimzelx 13
- Figure C - bimzelx 14
- Figure D - bimzelx 15
- Figure E - bimzelx 16
- Figure F - bimzelx 17
- Figure G - bimzelx 18
- Figure H - bimzelx 19
- Figure I - bimzelx 20
- Figure J - bimzelx 21
- PRINCIPAL DISPLAY PANEL - 160 mg/mL Autoinjector Carton - bimzelx 22
- PRINCIPAL DISPLAY PANEL - 160 mg/mL Syringe Carton - bimzelx 23
Product Label Images
The following 23 images provide visual information about the product associated with Bimzelx NDC 50474-783 by Ucb, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 2 - bimzelx 02

The given text contains information regarding the PASI90 Response Rate for different treatment groups over a period of 48 weeks. The treatment groups include Bimekizumab 320mg Q4W/Placebo, Bimekizumab 320mg Q4W/Bimekizumab 320mg Q8W, and Bimekizumab 320mg Q4W/Bimekizumab 320mg Q4W. The number of participants in each group is mentioned, with the first group having 105 participants, the second group having 100 participants, and the third group having 106 participants.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.